Compass Pathways
Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles
Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA
A New Dawn for Psychedelics: Compass Pathways Nears Major Phase 3 Psilocybin Results
Compass Pathways; COMP360; psilocybin; treatment-resistant depression; phase 3 trial; psychedelic therapy; FDA Breakthrough Therapy; mental health innovation
Compass Pathways Delays Phase 3 Psilocybin Trials, Cuts 30% of Workforce to Conserve Cash
Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development